Analystreport

UroGen Pharma Ltd. (NASDAQ: URGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $22.00 to $16.00. They now have a "neutral" rating on the stock.

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com